Core C: Biospecimen and Pathology Core

核心 C：生物样本和病理学核心

基本信息

批准号：
10006078
负责人：
MICHAEL S TORBENSON
金额：
$ 34.35万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-10 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10006078
关键词：
Address Aliquot Animal Model Arizona Bacterial Artificial Chromosomes Basic Science Biliary Bioinformatics Biological Specimen Banks Biometry Biopsy Blood Blood Platelets Blood specimen Cancer Model Cancer Patient Cell Line Cessation of life Characteristics Cholangiocarcinoma Clinic Clinical Clinical Data Clinical Research Consent Core Facility DNA Data Databases Development Diagnosis Diagnostic Dietary History Disease Early Diagnosis Evaluation Excision Family Fibrolamellar Hepatocellular Carcinoma Florida Formalin Freezing Frozen Sections Funding Future Genes Genetic Genomic DNA Goals Hepatobiliary Histology Human Immunocompetent Immunohistochemistry Individual Infrastructure International Joints Knock-out Knockout Mice Laboratories Liver Maintenance Malignant Neoplasms Malignant neoplasm of liver Mayo Clinic Cancer Center Medical History Medidata Molecular Analysis Molecular Genetics Neoplasms Online Systems Operative Surgical Procedures Outcome Paraffin Paraffin Embedding Pathologic Pathology Patient-Focused Outcomes Patients Pharmaceutical Preparations Phenotype Plasma Prevention strategy Process Program Research Project Grants Recording of previous events Registries Research Research Personnel Research Project Grants Resected Resource Sharing Resources Risk Factors Sampling Serum Services Site Sleeping Beauty Specimen Stains The Cancer Genome Atlas Tissue Embedding Tissue Microarray Tissues Toxin Transgenic Mice Transgenic Organisms Translational Research Tumor stage Universities Unresectable Vision Xenograft procedure anticancer research base biobank burden of illness cancer site career cholestatic liver disease data acquisition demographics digital imaging disease registry early phase clinical trial genetic analysis hepatobiliary cancer improved liver transplantation mouse model prevent programs prospective repository response therapy outcome transplant registry tumor virtual

项目摘要

CORE C BIOSPECIMEN AND PATHOLOGY – PROJECT SUMMARY The Biospecimen and Pathology Core (Core C) will be responsible for accessioning and processing new biospecimens with annotated clinical data to provide the needed biospecimens for the four SPORE translational research projects, for the Developmental Research and Career Enhancement Programs, and for other investigators engaged in hepatobiliary cancer research. Core C will build on the existing International Hepatobiliary Neoplasia Registry and Biorepository, which has been coordinated by Dr. Lewis Roberts since 2001, and collaborate with additional existing biorepositories including the Genetics of Cholestatic Liver Diseases Registry, coordinated by Dr. Konstantinos Lazaridis, the Liver Transplant Registry coordinated by Dr. Kymberly Watt, and the Hepatobiliary Neoplasia Patient Derived Xenograft program which is jointly coordinated by Dr. Mark Truty and Dr. Roberts. Core C will also coordinate with The Fibrolamellar Hepatocellular Carcinoma Biorepository at the Rockefeller University under Dr. Sanford Simon, which will become part of the Core infrastructure. Core C will provide sample accessioning and pathology support for the early phase clinical trials as needed in the SPORE projects. Core C will coordinate with the Mayo Clinic Cancer Center Biospecimen Accessioning and Processing (BAP) Shared Resource to process blood samples to genomic DNA and serum and plasma aliquots, and with the Pathology Research Core (PRC) Shared Resource to provide histology and other tissue-based services, including paraffin and frozen sectioning, immunohistochemistry, tissue microarray (TMA) construction, and digital imaging. Requests for biospecimens will be reviewed by the Biospecimen Access Committee for Hepatobiliary Cancers (BAC-HEP), with priority access for SPORE investigators and consideration given primarily to scientific merit and availability of biospecimens. Input from the Biostatistics and Bioinformatics Core will be included in the evaluation of biospecimen requests. Dr. Torbenson will provide detailed annotation of the SPORE's tissue database for frozen and formalin-fixed paraffin-embedded tissues of all available patients who have had surgical resections for hepatobiliary cancer at Mayo Clinic, as well as for PDXs, a number of which are derived from percutaneous biopsies of patients with intermediate to advanced unresectable and metastatic disease. The availability of PDXs from biopsies of more advanced tumors will help to address the concern that most of the genetic and molecular analyses of liver and biliary tumors performed thus far, including for example, within The Cancer Genome Atlas project (TCGA), has been performed on early stage surgically resected tumors, not on the intermediate to advanced and metastatic stage tumors for which advances in therapy are urgently needed. Dr. Torbenson will also interpret IHC staining and provide other pathology support such as evaluating tumor samples from Sleeping Beauty, transgenic or knockout mouse models of liver and biliary cancer.

核心C生物测量和病理学 - 项目摘要生物测量和病理核心（核心C）将负责加入和处理新的带有带注释的临床数据的生物测量，为四个孢子提供所需的生物测量转化研究项目，发展研究和职业增强计划，以及其他研究人员从事肝胆癌症研究。核心将建立在现有国际的基础上肝小毒性肿瘤注册表和生物座席，从那以后一直由Lewis Roberts博士协调 2001年，并与其他现有的生物膜合作，包括胆汁淤积的遗传学疾病登记处，由康斯坦丁诺斯·拉扎里迪斯（Konstantinos Lazaridis）博士协调，肝移植注册表由博士协调 Kymberly Watt和Hepatobilary肿瘤患者衍生的异种移植计划由Mark Truty博士和Roberts博士协调。 Core C还将与纤维骨架协调洛克菲勒大学的肝细胞癌生物库，桑福德·西蒙（Sanford Simon）成为核心基础架构的一部分。核心C将为样本登录和病理支持孢子项目的早期临床试验。 Core C将与Mayo临床癌进行协调中心生物循环登录和处理（BAP）共享资源以处理血样基因组DNA，血清和血浆等分试样，以及病理研究核心（PRC）共享提供组织学和其他基于组织的服务的资源，包括石蜡和冷冻切片，免疫组织化学，组织微阵列（TMA）结构和数字成像。 Bispecimen访问委员会将审查生物含量的请求肝癌症（BAC-HEP），具有孢子研究人员的优先访问，并考虑了科学功绩和生物测量的可用性。生物统计学和生物信息学核心的输入将包括在评估生物测量请求。 Torbenson博士将提供孢子组织的详细注释所有曾经有过的患者 Mayo诊所以及PDXS的肝胆癌的外科手术切除术，其中许多是衍生的来自患有中间至晚期不可切除和转移性疾病的患者的经皮活检。来自更高级肿瘤活检的PDX的可用性将有助于解决大多数的关注迄今为止，肝脏和胆道肿瘤的遗传和分子分析，包括癌症基因组图集项目（TCGA）已在早期手术切除的肿瘤上进行，而不是在中间到晚期和转移性阶段肿瘤上，治疗的进展是迫切的需要。 Torbenson博士还将解释IHC染色并提供其他病理支持，例如评估来自睡美人，转基因或敲除小鼠肝癌和胆道癌的肿瘤样品。